Deferiprone as an oral iron chelator in sickle cell disease

Annals of Hematology

Volumn 84, Issue 7, 2005, Pages 434-440

  Voskaridou, Ersi ^a   Douskou, Maroussa ^b   Terpos, Evangelos ^c   Stamoulakatou, Alexandra ^d   Meletis, John ^e   Ourailidis, Akis ^b   Papassotiriou, Ioannis ^d   Loukopoulos, Dimitris ^f  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b BIOIATRIKI HEALTHCARE GROUP   (Greece)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^d AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f Academy of Athens Biomedical Research Foundation   (Greece)

Author keywords

Deferiprone; Iron overload; Liver; Magnetic resonance imaging; Sickle cell disease

Indexed keywords

DEFERIPRONE; FERRITIN; IRON; IRON CHELATING AGENT;

ADULT; AGED; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; MALE; MEDICAL ASSESSMENT; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELIABILITY; SICKLE CELL ANEMIA; SIDE EFFECT; TREATMENT OUTCOME; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; DRUG EVALUATION; FEMALE; FERRITINS; HEART; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRIDONES;

EID: 20944435298     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1015-7     Document Type: Article

References (39)

1. Adams RJ, Mckie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339:5-11 10.1056/NEJM199807023390102
2. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Laulicht M, Fenton LA, Scheuer PJ, Kibbler CC, Allwood CA, Brown D (1987) Iron state and hepatic disease in patients with thalassemia major treated with long term subcutaneous desferrioxamine. J Clin Pathol 40:1353-1359
3. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ (1992) Efficacy and possible adverse effects of the oral chelator 1,2 dimethyl-3-hydraxypyrid-4-one (Li) in thalassemia major. Blood 80:593-599
4. Al-Refaie FN, Shephard LN, Nortey P, Wonke B, Hoffbrand AV (1995) Pharmacokinetics of the oral chelator deferiprone (L1) in patients with iron overload. Br J Haematol 89:403-408
5. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-Star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171-2179
6. Banarjee S, Owen C, Chopra S (2001) Sickle cell hepatopathy. Hepatology 33:1021-1028
7. Bower TW, Moore GW, Hutchins GM (1980) The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med 69:833-837
8. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42:81-85 1:STN:280:ByyD1MfitVc%3D
9. Brittenham GM, Griffith PM, Nienhuis AW (1994) Efficacy of desferrioxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567-573
10. Brittenham GM, Badman DG (2003) Noninvasive measurement of iron: Report of an NIDDK workshop. Blood 101:15-19 10.1182/blood-2002-06-1723
11. Charache S (1981) Treatment in sickle cell anemia. Annu Rev Med 32:195-206
12. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317-1322 10.1056/ NEJM199505183322001
13. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102:1583-1587
14. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF (1994) Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 83:2329-2333
15. Davies SC, Roberts-Harewood M (1997) Blood transfusion in sickle cell disease. Blood Rev 11:57-71
16. Davis BA, Porter JB (2000) Long-term outcome of continuous 24-hour deferiprone infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95:1229-1236
17. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider R, Piga A (2003) Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassemia major: Application of SQUID biomagnetic liver susceptometry. Br J Haematol 121:938-948
18. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y (2004) Non-invasive assessment of hepatic iron stores by MRI. Lancet 363:357-362
19. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E (2000) Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 96:76-79
20. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overload patients. Blood 91:295-300
21. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L (1987) Effective chelation of iron in beta thalassaemia with the oral chelator 1,2 dimethyl-3-hydroxypyrid-4-one. Br Med J Clin Res Ed 295:1509-1512
22. Kontoghiorghes GJ, Goddurd JG, Bartlett AN, Sheppard L (1990) Pharmacokinetic studies in humans with the oral iron chelator 1,2 dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 48:255-261
23. Loukopoulos L, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I (2000) Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: The experience of a single center in Greece. Blood Cells Mol Dis 26:453-466
24. Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the United Kingdom: Data from the UK thalassaemia register (letter). Lancet 355:2051-2052 10.1016/S0140-6736(00)02357-6
25. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G (1995) Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918-922
26. Olivieri NF, Brittenham GM (1997) Iron chelation therapy and treatment of thalassemia. Blood 89:739-761 1:CAS:528:DyaK2sXptVGntg%3D%3D
27. Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 88:489-496
28. Platt OS, Brambilla DJ, Rosse WC, Milner PF, Castro O, Steinberg MH, Klugg PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639-1644 10.1056/ NEJM199406093302303
29. Porter JB, Herhns ER (1987) Transfusion and exchange transfusions in sickle cell anemias with particular reference to iron metabolism. Acta Haematol 78:198-205
30. Porter JB, Davis AB (2002) Monitoring chelation to achieve optimal outcome in the treatment of thalassemia. Best Pract Res Clin Haematol 15:329-368
31. Rosenblate HJ, Eisenstein R, Holmes AW (1970) The liver in sickle cell anaemia. A clinical-pathologic study. Arch Pathol 90:235-243
32. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP (1995) Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 86:2008-2013
33. Shalev O, Hileti D, Nortey P, Hebbel RP, Hoffbrand VA (1999) Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol 105:1081-1083
34. St. Pierre TG, Clark PR, Chua-Anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R (2005) Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855-861
35. Vichinsky EP, Neumayr LD, Haberkern C, Earles AN, Eckman J, Koshy M, Black DM (1999) The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the National Sickle Cell Surgery Study Group. Am J Hematol 62:129-138
36. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM (2003) Tissue Doppler echocardiography in patients with thalassemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 24:113-119
37. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D (2004) Magnetic resonance imaging (MRI) in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 126:736-742
38. Wayne AS, Kevy SV, Nathan DG (1993) Transfusion management of sickle cell disease. Blood 81:1109-1123
39. Wood JC, Tyszka JM, Carson S, Nelson M, Coates T (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103:1934-1936